Skip to main content
Top of the Page
The Society

About SOHO

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 6,000 members from 110 countries have joined the society from around the globe.

SOHO is an international society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field.

Society Structure

SOHO is led by a Board of Directors with eight voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO.

Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively. A third committee, Publication, is responsible for identifying opportunities for publishing work derived from the Society's activities. In addition, members of the Publication Committee manage the publication of papers for the society's featured article series, "SOHO State of the Art and Next Questions." Members of these groups are listed on the 'Committees' webpage.

Annual Meeting

The SOHO annual meeting has no parallel general sessions so that delegates may attend all sessions in sequential order. In addition, presentations are limited to the ‘latest advances’ allowing all topics to be covered in only 3.5 days. Last year, nearly 2,300 hematologic oncology experts gathered from around the world to share the latest clinical research impacting patient treatment at the virtual 9th Annual Meeting of the Society of Hematologic Oncology. 

The tenth annual meeting of the society, SOHO 2022, will be held as a hybrid event (in-person AND virtual) on September 28-October 1, 2022. Advances in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes and related malignancies will be highlighted during the official educational program. For more information and to register, visit

Official Journal

Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (see journal).

News Publication

Blood Cancers Today,” is an official publication of the Society of Hematologic Oncology. BCT is a news-format publication that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings. It is available online free-of-charge to the public and in print form free-of-charge to SOHO members (see BCT).


Become a Member



Neurotoxicity Acceptable in CD19 CAR-T Cell Therapy for B-ALL with CNS Leukemia

Posted on 4/8/2022
CD19-directed CAR-T cell therapy could induce similar high response rates in patients with B-cell acute lymphoblastic leukemia with central nervous system leukemia.

News-Blood Cancers Today

Posted on 3/20/2022
BCT RSS News Feed - Blood Cancers Today (BCT) delivers the latest news, education, and information relevant to hematologic oncology patients and practices, with important insights from experts in the field.

Risk for Neurologic Adverse Events Less with Immune Checkpoint Inhibitors

Posted on 4/21/2022
The use of immune checkpoint inhibitors is associated with a decreased likelihood of developing neurologic adverse events compared with other cancer medications, particularly cytotoxic chemotherapy.

FDA Approves Axi-Cel as Initial Treatment for Relapsed, Refractory LBCL

Posted on 4/14/2022
The CAR T-cell therapy was approved for adults with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or that relapsed within 12 months of first-line treatment.

IDH Mutation Location Affected Relapse Risk After AML Transplant

Posted on 4/8/2022
Certain IDH mutation locations had a higher association with risk of AML relapse after transplant.


The Society of Hematologic Oncology advocates our mission by uniting members around the world to discuss and unify the most advanced management and treatment approaches for patients with hematologic malignancies.

We initiate and manage programs with practices, cancer centers and countries, presenting the latest data and sharing new ways to treat and cure diseases within this complex group of malignancies.

Discussion topics

Back to Top